Lund, Sweden, 2012-04-05 09:24 CEST (GLOBE NEWSWIRE) --
Recently two very interesting studies were published. One in the Journal of Clinical Oncology on Bone Scan Index (BSI) as an important imaging biomarker and one in EUROPEAN UROLOGY regarding the advantages of calculating the BSI using EXINI's software EXINI bone™. Both studies were performed at Memorial Sloan-Kettering Cancer Center in New York, and have been reproduced on several occasions in other reputable medical news media.
Results from the study with EXINI bone show that the automatic analysis provides a more objective and faster calculation of BSI (Bone Scan Index) compared to the currently time-consuming manual method. This makes the BSI as a clinical routine method possible to use in prediction of survival, therapy monitoring and clinical trials of new drugs in prostate cancer patients.
"Incredibly exciting what interest the articles and the BSI have created. Through the wide interest in the articles the knowledge about BSI has increased among the specialist medical community for cancer treatment. This will give an increasing impact on an important new marker for prediction of survival and monitoring of prostate and breast cancer patients. says Magnus Aurell CEO EXINI Diagnostics AB
Read the articles:
PROSTATE CANCER FOUNDATION, 29 Jan 2012
”Pcf-funding leads to new bone scale index to measure remissions in bone metastases”
länk till artikel >>
MODERN MEDICINE, 12 Jan 2012
”Bone scale helps determine response to prostate Ca treatment”
länk till artikel >>
MD NEWS, Feb 1 2012
”Change in Bone Scan Index Predicts Prostate CA Survival”
länk till artikel >>
ECANCERNEWS - THE LATEST ONCOLOGY HEADLINES, 23 Jan 2012
”Bone Scan Index predicts survival in prostate cancer”
länk till artikel >>
INVESTIGATIONAL DRUG STEERING COMMITTEE, Feb 2012
”A novel automated platform for quantifying the extent of skeletal tumor involvement in prostate cancer patients using the bone scan index, a study by Ulmert et” al was highlighted as a key announcement in the IDSC 12th newsletter.”
länk till artikel >>
NATURE REVIEWS UROLOGY, Feb 2012
”Prostate cancer: Bone scan index—a new imaging biomarker?”
länk till artikel >>
For more information, please contact:
Magnus Aurell, CEO
Phone: +46 46 286 54 25
E-mail: magnus.aurell@exini.com
About EXINI Diagnostics AB (publ)
EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 400 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkomission AB acts as Certified Adviser.
________________________________________________________________________
EXINI Diagnostics AB, Ideon Science Park, Scheelevägen 19A, SE-223 70 Lund, Sweden
Phone: +46 46 286 54 20, Fax: +46 46 286 54 29, info@exini.com, www.exini.com
